FDA grants accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for metastatic colorectal cancer
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn how
The FDA granted an accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
Find out more about the approval in this Onclive article.
